OPEX® Introduces the Next Generation in Goods-to-Person Warehouse Automation Technology - Infinity™ ASRS
28.3.2022 13:00:00 EEST | Business Wire | Press release
OPEX® Corporation, a global leader in warehouse automation technology, has added an innovative, industry-leading goods-to-person (G2P) solution to its Warehouse Automation portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005036/en/
The Infinity Goods-to-Person (G2P) solution (Photo: Business Wire)
The Infinity™ solution combines unparalleled storage density, configurability, and flexibility to meet the most pressing warehouse automation challenges for companies handling micro-fulfillment, omni-channel distribution, store replenishment, and ecommerce.
“Our focus is on engineering exciting new solutions that address unmet and evolving customer needs,” said Alex Stevens, President, OPEX Warehouse Automation. “The Infinity solution represents the next generation of goods-to-person technology to perfectly complement our existing Warehouse Automation product line.”
Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput, and labor utilization by eliminating wasted time.
Powered by OPEX’s proprietary Cortex™ software platform, the Infinity G2P solution is engineered for maximum flexibility and scalability in both throughput and storage. Key benefits include reducing labor while increasing efficiency, storage density, and configurability.
Wireless Infinity iBOT® robotic vehicles access all inventory and port stations, moving freely underneath and throughout the system with no wasted mechanical motion, saving time and costs. Infinity iBOT robots are easily scalable by adding more iBOTs, presentation ports, and grids.
Unlike other competitive systems, the Infinity solution offers up to 35 percent more storage capacity with bot paths that are up to 65 percent more efficient.
The Infinity goods-to-person system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The Infinity system’s flexibility also accommodates varied workflows and layouts.
The innovative Infinity solution was unveiled today at MODEX 2022, the industry’s premier material handling expo that showcases the latest in manufacturing and supply chain technology.
“Ecommerce is growing exponentially,” said Stevens. “Companies today need dependable yet advanced technology, the resiliency to meet shifting and seasonal demands, fast and accurate fulfillment, the ability to maximize space, and a partner they can trust. OPEX and the Infinity solution deliver all of this and more.”
Founded in 1973, OPEX brings generations of industry expertise and a proven track record developing first-class automation capabilities. The company is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all of its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.
The Infinity solution joins the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; and Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability. All three solutions are custom configured for each client and designed to completely transform supply chain infrastructure.
To learn more, please visit warehouseautomation.com.
About OPEX
OPEX Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005036/en/
Contact information
Colleen Ciak
cciak@opex.com
+1 856.727.1100, ext. 5350
+1 856.912.4952 Cell
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom